JCO Early Release, published online ahead of print Apr 2 2007
Journal of Clinical Oncology, 10.1200/JCO.2006.10.1949
Received December 11, 2006
Accepted February 13, 2007
Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2006 Update of an American Society of Clinical Oncology Practice Guideline
D. Andrew Loblaw, Katherine S. Virgo, Robert Nam, Mark R. Somerfield, Edgar Ben-Josef, David S. Mendelson, Richard Middleton, Stewart A. Sharp, Thomas J. Smith, James Talcott, Maryellen Taplin, Nicholas J. Vogelzang, James L. Wade III, Charles L. Bennett, and Howard I. Scher
From the American Society of Clinical Oncology, Alexandria, VA.
Purpose: To update the 2004 American Society of Clinical Oncology (ASCO) guideline on initial hormonal management of androgen-sensitive, metastatic, recurrent, or progressive prostate cancer (PCa).
Methods: The writing committee based its recommendations on an updated systematic literature review. Recommendations were approved by the Expert Panel, the ASCO Health Services Committee, and the ASCO Board of Directors.
Results: Seven randomized controlled trials (four new), one systematic review, one meta-analysis (new), one Markov model, and one delta-method 95% CI procedure for active controlled trials (new) informed the guideline update.
Recommendations: Bilateral orchiectomy or luteinizing hormone-releasing hormone agonists are recommended initial androgen-deprivation treatments (ADTs). Nonsteroidal antiandrogen monotherapy merits discussion as an alternative; steroidal antiandrogen monotherapy should not be offered. Combined androgen blockade should be considered. In metastatic or progressive PCa, immediate versus symptom-onset institution of ADT results in a moderate decrease (17%) in relative risk (RR) for PCa-specific mortality, a moderate increase (15%) in RR for non-PCa-specific mortality, and no overall survival advantage. Therefore, the Panel cannot make a strong recommendation for early ADT initiation. Prostate-specific antigen (PSA) kinetics and other metrics allow identification of populations at high risk for PCa-specific and overall mortality. Further studies must be completed to assess whether patients with adverse prognostic factors gain a survival advantage from immediate ADT. For patients electing to wait until symptoms for ADT, regular monitoring visits are indicated. For patients with recurrence, clinical trials should be considered if available. Currently, data are insufficient to support use of intermittent androgen blockade outside clinical trials.
To whom correspondence should be addressed: American Society of Clinical Oncology, 1900 Duke St, Ste 200, Alexandria, VA 22314; e-mail: guidelines@asco.org.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
W. Dale, J. Hemmerich, K. Bylow, S. Mohile, M. Mullaney, and W. M. Stadler
Patient Anxiety About Prostate Cancer Independently Predicts Early Initiation of Androgen Deprivation Therapy for Biochemical Cancer Recurrence in Older Men: A Prospective Cohort Study
J. Clin. Oncol.,
April 1, 2009;
27(10):
1557 - 1563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-N. Wong, S. Freedland, B. Egleston, G. Hudes, J. S. Schwartz, and K. Armstrong
Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer
J. Clin. Oncol.,
January 1, 2009;
27(1):
100 - 105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Soga, K. Arima, and Y. Sugimura
Undetectable Level of Prostate Specific Antigen (PSA) Nadir Predicts PSA Biochemical Failure in Local Prostate Cancer with Delayed-combined Androgen Blockade
Jpn. J. Clin. Oncol.,
September 1, 2008;
38(9):
617 - 622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N Howard, C. Chambers, and F. Cusano
Efficacy vs. effectiveness -- docetaxel and prednisone in hormone refractory prostate cancer
Journal of Oncology Pharmacy Practice,
March 1, 2008;
14(1):
45 - 49.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. Arap, M. Trepel, B. R. Zetter, and R. Pasqualini
Meeting Report: Innovations in Prostate Cancer Research
Cancer Res.,
February 1, 2008;
68(3):
635 - 638.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tomioka, M. Shimbo, Y. Amiya, H. Nakatsu, S. Murakami, and J. Shimazaki
Outcome of Patients with Hormone-Refractory Prostate Cancer: Prognostic Significance of Prostate-Specific Antigen-Doubling Time and Nadir Prostate-Specific Antigen
Jpn. J. Clin. Oncol.,
January 1, 2008;
38(1):
36 - 42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. I. Pritchard
Adjuvant Endocrine Therapy of the Future: Potential and Possibilities
ASCO Educational Book,
January 1, 2008;
2008(1):
18 - 23.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
ASCO Practice Guidelines for Initial Hormonal Management of Prostate Cancer
Journal Watch Oncology and Hematology,
May 14, 2007;
2007(514):
3 - 3.
[Full Text]
|
|
|
|
|
|
|
2007 Update of ASCO Practice Guideline for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: Guideline Summary
J. Oncol. Pract,
May 1, 2007;
3(3):
175 - 177.
[Full Text]
[PDF]
|
|
|
|
